These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 1803623)
1. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females. Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623 [TBL] [Abstract][Full Text] [Related]
2. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655 [TBL] [Abstract][Full Text] [Related]
3. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812 [TBL] [Abstract][Full Text] [Related]
4. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Tran-Thang C; Fasel-Felley J; Pralong G; Hofstetter JR; Bachmann F; Kruithof EK Thromb Haemost; 1989 Sep; 62(2):651-3. PubMed ID: 2510345 [TBL] [Abstract][Full Text] [Related]
5. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation. Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164 [TBL] [Abstract][Full Text] [Related]
6. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity]. Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860 [TBL] [Abstract][Full Text] [Related]
7. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Siegbahn A; Ruusuvaara L Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043 [TBL] [Abstract][Full Text] [Related]
8. Selected parameters of fibrinolysis system in patients with dermatitis herpetiformis. Wankiewicz A; Iwan-Zietek I; Kotschy M; Gwieździński Z Med Sci Monit; 2002 Mar; 8(3):CR189-92. PubMed ID: 11887034 [TBL] [Abstract][Full Text] [Related]
9. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes. Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392 [TBL] [Abstract][Full Text] [Related]
10. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541 [TBL] [Abstract][Full Text] [Related]
11. Physical exercise induces enhancement of urokinase-type plasminogen activator (u-PA) levels in plasma. Dooijewaard G; de Boer A; Turion PN; Cohen AF; Breimer DD; Kluft C Thromb Haemost; 1991 Jan; 65(1):82-6. PubMed ID: 1902597 [TBL] [Abstract][Full Text] [Related]
12. [Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]. Xiao W; Tong WL; Ma DD Zhonghua Jie He He Hu Xi Za Zhi; 2006 Nov; 29(11):723-6. PubMed ID: 17327049 [TBL] [Abstract][Full Text] [Related]
13. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Declerck PJ; Verstreken M; Collen D Thromb Haemost; 1995 Nov; 74(5):1305-9. PubMed ID: 8607114 [TBL] [Abstract][Full Text] [Related]
14. A specific immunologic assay for functional plasminogen activator inhibitor 1 in plasma--standardized measurements of the inhibitor and related parameters in patients with venous thromboembolic disease. Philips M; Juul AG; Selmer J; Lind B; Thorsen S Thromb Haemost; 1992 Nov; 68(5):486-94. PubMed ID: 1455392 [TBL] [Abstract][Full Text] [Related]
15. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. Asselbergs FW; Williams SM; Hebert PR; Coffey CS; Hillege HL; Navis G; Vaughan DE; van Gilst WH; Moore JH Thromb Haemost; 2006 Oct; 96(4):471-7. PubMed ID: 17003924 [TBL] [Abstract][Full Text] [Related]
16. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium. Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554 [TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968 [TBL] [Abstract][Full Text] [Related]
18. Fibrinolysis system in patients with bronchial asthma. Banach-Wawrzeńczyk E; Dziedziczko A; Rość D Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies. Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431 [TBL] [Abstract][Full Text] [Related]
20. [Hypofibrinolysis after venous occlusion in patients treated with long-term hemodialysis]. Opatrný K; Vít L; Opatrná S; Sulková S; Bodláková B Cas Lek Cesk; 1994 May; 133(11):346-9. PubMed ID: 8004664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]